farnesol has been researched along with cyclin d1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, R; Elkon, R; Goldberg, L; Kloog, Y; Nakdimon, I; Rechavi, G; Shamir, R | 1 |
| Blum, R; Erlich, S; Karunagaran, D; Kloog, Y; Liebling, R; Pinkas-Kramarski, R; Tal-Or, P | 1 |
| Charette, N; De Saeger, C; Horsmans, Y; Lannoy, V; Leclercq, I; Stärkel, P | 1 |
| Alves, V; Andrade, C; Casalta-Lopes, J; Costa, CB; Dourado, M; Gonçalves, AC; Moreira, D; Nascimento-Costa, JM; Oliveira, A; Sarmento-Ribeiro, AB; Silva, T | 1 |
| Abramovitch, S; Elad-Sfadia, G; Haklai, R; Kloog, Y; Neeman, R; Reif, S; Sharvit, E | 1 |
| Fukushima, S; Minegaki, T; Morioka, C; Nishiguchi, K; Takanashi, H; Tsuji, S; Tsujimoto, M; Uno, J; Watanabe, A; Yamamoto, S | 1 |
6 other study(ies) available for farnesol and cyclin d1
| Article | Year |
|---|---|
E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; E2F1 Transcription Factor; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Green Fluorescent Proteins; Humans; Immunoblotting; Immunohistochemistry; Luciferases; Phosphorylation; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; ras Proteins; Recombinant Fusion Proteins; Retinoblastoma Protein; Salicylates | 2006 |
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Androgens; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; E2F1 Transcription Factor; Farnesol; Humans; Male; Myotonin-Protein Kinase; Prostatic Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; Salicylates; Serine Proteinase Inhibitors; Signal Transduction | 2006 |
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor II; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Salicylates; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Farnesyltransferase inhibitors: molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin D1 inhibition.
Topics: Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; Organophosphonates; Phosphorous Acids; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2012 |
Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Topics: Animals; Biomarkers; Calcitriol; Cell Proliferation; Cyclin D1; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Farnesol; Gene Expression Regulation; Hepatic Stellate Cells; Male; ras Proteins; Rats; Rats, Wistar; Salicylates | 2014 |
Effects of bisphosphonates on human esophageal squamous cell carcinoma cell survival.
Topics: Annexins; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin D1; Diphosphonates; Diterpenes; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Farnesol; G1 Phase Cell Cycle Checkpoints; Humans; Squalene | 2016 |